Diseases [C] » Musculoskeletal Diseases [C05] » Muscular Diseases » Muscular Disorders, Atrophic » Muscular Dystrophies
Diseases [C] » Nervous System Diseases [C10] » Neuromuscular Diseases » Muscular Diseases » Muscular Disorders, Atrophic » Muscular Dystrophies
Diseases [C] » Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] » Genetic Diseases, Inborn » Muscular Dystrophies
Description
A heterogeneous group of inherited MYOPATHIES, characterized by wasting and weakness of the SKELETAL MUSCLE. They are categorized by the sites of MUSCLE WEAKNESS; AGE OF ONSET; and INHERITANCE PATTERNS. MeSH
Hierarchy View
Subtype Terms (9)
Glycogen Storage Disease Type VII
2 drugs (1 approved, 1 experimental)
Muscular Dystrophies, Limb-Girdle
16 drugs (4 approved, 12 experimental)
Muscular Dystrophy, Duchenne
101 drugs (43 approved, 58 experimental)
Muscular Dystrophy, Emery-Dreifuss
Muscular Dystrophy, Facioscapulohumeral
13 drugs (6 approved, 7 experimental)
Muscular Dystrophy, Oculopharyngeal
4 drugs (1 approved, 3 experimental)
Myotonic Dystrophy
14 drugs (7 approved, 7 experimental)
Approved Indicated Drugs (6)
Phase 4 Indicated Drugs (2)
Phase 3 Indicated Drugs (5)
Phase 2 Indicated Drugs (4)
Phase 1 Indicated Drugs (6)
Other Experimental Indicated Drugs (6)
Organization Involved with Phase 4 Indications (9)
Organization Involved with Phase 3 Indications (60)
Children's National Medical Center
Chinese Academy of Medical Sciences
Cooperative International Neuromuscular Research Group
Federal University of Minas Gerais
Katholieke Universiteit Leuven
Methodist Cancer Center, Houston, Texas
National Center for Research Resources (NCRR)
National Institute of Neurological Disorders and Stroke (NINDS)
The Charlotte-Mecklenburg Hospital Authority
The University of Texas, Dallas
Universidad Complutense de Madrid
University of California, Davis
University of California, Los Angeles
Organization Involved with Phase 2 Indications (61)
Foundation to Eradicate Duchenne
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Instituto Mexicano del Seguro Social
Instituto Nacional de Rehabilitacion
National Center of Neurology and Psychiatry, Japan
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Organization Involved with Phase 1 Indications (26)
Organization Involved with Other Experimental Indications (8)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
